COMMUNIQUÉS West-GlobeNewswire

IBA reports Half Year 2026 results, on track with its improved profitability trajectory
27/08/2026
Louvain-la-Neuve, Belgium, 27 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A.), today announces its consolidated results for the first half of 2026, with performance on track with FY 2026 guidance and continued [...]
IBA publie ses résultats semestriels 2026, et confirme sa trajectoire d’amélioration de la rentabilité
27/08/2026
Louvain-La-Neuve, Belgique, 27 août 2026, 7h00 - IBA (Ion Beam Applications S.A.), annonce aujourd’hui ses résultats consolidés pour le premier semestre 2026, avec une performance conforme aux prévisions pour l’exercice [...]
Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates
27/08/2026
SHANGHAI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Mesoblast Reports Substantial Revenue Growth to US$120M
27/08/2026
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: [...]
Onco360® Has Been Selected as a National Pharmacy Partner for RASONQUE™ (daraxonrasib)
27/08/2026
LOUISVILLE, Ky., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, is grateful to be selected as a pharmacy partner by Revolution Medicines for RASONQUE™ (daraxonrasib), [...]
Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions
26/08/2026
AUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience [...]
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
26/08/2026
- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s [...]
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
26/08/2026
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, [...]
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
26/08/2026
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in [...]
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
26/08/2026
European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart’s Norovirus vaccine program through at least 2036 across key European markets KEY HIGHLIGHTS: • European Patent [...]
Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting
26/08/2026
PARSIPPANY, NJ, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”), an emerging leader in enabling personalized medicine, today announced that it will effect a 1- [...]
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
26/08/2026
Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results New poster will highlight the mechanistic characterization of azetukalner, including its potential additive [...]
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
26/08/2026
RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy In the [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
26/08/2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 26 août 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
EssilorLuxottica: Disclosure of transactions in own shares
26/08/2026
Disclosure of transactions in own shares Paris, France (August 26, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 28, 2026, EssilorLuxottica declares that [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
26/08/2026
Déclaration de transactions sur actions propres Paris, France (26 août 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 28 avril 2026, EssilorLuxottica déclare que du 17 août 2026 au 21 [...]
RAMSAY SANTE : Provisional annual results at the end of June 2026
26/08/2026
PRESS RELEASE Paris, 26 th August 2026 Provisional annual results at the end of June 2026 Revenue growth and disciplined efficiency drive stronger operational profitability Capital Markets Day on 17 th September: Ramsay [...]
RAMSAY SANTE : Résultats annuels provisoires à fin juin 2026
26/08/2026
COMMUNIQUE DE PRESSE Paris, 26 août 2026 Résultats annuels provisoires à fin juin 2026 Croissance du chiffre d’affaires et discipline financière contribuent à l’amélioration de la rentabilité opérationnelle Capital [...]
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
26/08/2026
JAMA Dermatology publication includes results from VALOR skin-specific secondary endpoints, with rapid and durable improvements seen for brepocitinib 30 mg compared to placebo across multiple dimensions of cutaneous [...]

Pages